Bulletin
Investor Alert

Regeneron Pharmaceuticals Inc.

NAS: REGN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 18, 2021, 7:11 p.m.

/zigman2/quotes/203149337/composite

$

516.00

Change

-0.22 -0.04%

Volume

Volume 10,678

Quotes are delayed by 20 min

/zigman2/quotes/203149337/composite

Today's close

$ 523.73

$ 516.22

Change

-7.51 -1.43%

Day low

Day high

$513.68

$523.00

Open

52 week low

52 week high

$441.00

$664.64

Open

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accele...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Valuation

P/E Current

17.16

P/E Ratio (with extraordinary items)

14.45

P/E Ratio (without extraordinary items)

15.83

Price to Sales Ratio

6.54

Price to Book Ratio

4.69

Price to Cash Flow Ratio

21.24

Enterprise Value to EBITDA

15.49

Enterprise Value to Sales

6.44

Total Debt to Enterprise Value

0.05

Efficiency

Revenue/Employee

931,393.00

Income Per Employee

385,093.00

Receivables Turnover

2.50

Total Asset Turnover

0.53

Liquidity

Current Ratio

3.63

Quick Ratio

2.91

Cash Ratio

1.33

Profitability

Gross Margin

84.04

Operating Margin

38.79

Pretax Margin

44.84

Net Margin

41.35

Return on Assets

21.98

Return on Equity

31.77

Return on Total Capital

25.83

Return on Invested Capital

27.53

Capital Structure

Total Debt to Total Equity

24.45

Total Debt to Total Capital

19.65

Total Debt to Total Assets

15.71

Long-Term Debt to Equity

24.45

Long-Term Debt to Total Capital

19.65

Officers and Executives

Name Age Officer Since Title
Dr. P. Roy Vagelos 90 1995 Chairman
Dr. Leonard S. Schleifer 66 1988 President, Chief Executive Officer & Director
Dr. George Damis Yancopoulos 59 1989 Co-President, Director & Chief Scientific Officer
Ms. Patrice Gilooly - 1998 Senior VP-Quality Assurance & Operations
Mr. Robert E. Landry 55 2013 Chief Financial Officer & Executive VP-Finance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/07/2021 Marion McCourt
EVP Commercial
1,000   Disposition at $495.63 per share. 495,630
05/07/2021 Marion McCourt
EVP Commercial
1,000   Derivative/Non-derivative trans. at $342.93 per share. 342,930
02/23/2021 P. Roy Vagelos
Director
137,998   Derivative/Non-derivative trans. at $458.48 per share. 63,269,323
02/23/2021 P. Roy Vagelos
Director
248,079   Derivative/Non-derivative trans. at $52.03 per share. 12,907,550
02/23/2021 P. Roy Vagelos
Director
1,921   Derivative/Non-derivative trans. at $52.03 per share. 99,949
02/01/2021 Arthur Frederick Ryan
Director
2   Disposition at $512.82 per share. 1,025
02/01/2021 Arthur Frederick Ryan
Director
4   Disposition at $509.28 per share. 2,037
02/01/2021 Arthur Frederick Ryan
Director
16   Disposition at $508.52 per share. 8,136
02/01/2021 Arthur Frederick Ryan
Director
22   Disposition at $507.39 per share. 11,162
02/01/2021 Arthur Frederick Ryan
Director
30   Disposition at $506.44 per share. 15,193
02/01/2021 Arthur Frederick Ryan
Director
17   Disposition at $505.6 per share. 8,595
02/01/2021 Arthur Frederick Ryan
Director
9   Disposition at $504.68 per share. 4,542
01/25/2021 Michael S. Brown
Director
2,480   Disposition at $554.32 per share. 1,374,713
01/25/2021 Michael S. Brown
Director
2,480   Derivative/Non-derivative trans. at $380.95 per share. 944,756
01/19/2021 P. Roy Vagelos
Director
414   Gift at $0 per share. 0
01/04/2021 George L. Sing
Director
248   Award at $0 per share. 0
01/04/2021 Arthur Frederick Ryan
Director
248   Award at $0 per share. 0
01/04/2021 Michael S. Brown
Director
248   Award at $0 per share. 0
01/04/2021 Joseph L. Goldstein
Director
248   Award at $0 per share. 0
01/04/2021 Marc Tessier-Lavigne
Director
248   Award at $0 per share. 0
01/04/2021 Christine A. Poon
Director
248   Award at $0 per share. 0
01/04/2021 N. Anthony Coles
Director
248   Award at $0 per share. 0
01/04/2021 Huda Y. Zoghbi
Director
248   Award at $0 per share. 0
01/04/2021 Bonnie L. Bassler
Director
248   Award at $0 per share. 0
01/04/2021 Arthur Frederick Ryan
Director
1   Disposition at $491.36 per share. 491
01/04/2021 Arthur Frederick Ryan
Director
4   Disposition at $490.69 per share. 1,962
01/04/2021 Arthur Frederick Ryan
Director
2   Disposition at $489.41 per share. 978
01/04/2021 Arthur Frederick Ryan
Director
5   Disposition at $488.26 per share. 2,441
01/04/2021 Arthur Frederick Ryan
Director
5   Disposition at $487.63 per share. 2,438
01/04/2021 Arthur Frederick Ryan
Director
5   Disposition at $486.77 per share. 2,433
01/04/2021 Arthur Frederick Ryan
Director
12   Disposition at $485.5 per share. 5,826
01/04/2021 Arthur Frederick Ryan
Director
7   Disposition at $484.79 per share. 3,393
01/04/2021 Arthur Frederick Ryan
Director
9   Disposition at $483.37 per share. 4,350
01/04/2021 Arthur Frederick Ryan
Director
13   Disposition at $482.3 per share. 6,269
01/04/2021 Arthur Frederick Ryan
Director
13   Disposition at $481.48 per share. 6,259
01/04/2021 Arthur Frederick Ryan
Director
14   Disposition at $480.57 per share. 6,727
01/04/2021 Arthur Frederick Ryan
Director
5   Disposition at $479.54 per share. 2,397
01/04/2021 Arthur Frederick Ryan
Director
1   Disposition at $478.89 per share. 478
01/04/2021 Arthur Frederick Ryan
Director
4   Disposition at $477.58 per share. 1,910
12/30/2020 George Damis Yancopoulos
President and Chief Scientific; Director
86,096   Derivative/Non-derivative trans. at $483.25 per share. 41,605,892
12/30/2020 George Damis Yancopoulos
President and Chief Scientific; Director
130,714   Derivative/Non-derivative trans. at $483.25 per share. 63,167,540
12/30/2020 George Damis Yancopoulos
President and Chief Scientific; Director
158,079   Derivative/Non-derivative trans. at $52.03 per share. 8,224,850
12/30/2020 George Damis Yancopoulos
President and Chief Scientific; Director
240,000   Derivative/Non-derivative trans. at $52.03 per share. 12,487,200
12/09/2020 P. Roy Vagelos
Director
2,439   Award at $0 per share. 0
12/09/2020 Andrew J. Murphy
EVP Research
1,929   Award at $0 per share. 0
12/09/2020 Andrew J. Murphy
EVP Research
8,285   Award at $0 per share. 0
12/09/2020 Neil Stahl
EVP Research and Development
1,688   Award at $0 per share. 0
12/09/2020 Daniel P. Van Plew
EVP & General Mgr Industrial O
5,000   Award at $0 per share. 0
12/09/2020 Daniel P. Van Plew
EVP & General Mgr Industrial O
1,930   Award at $0 per share. 0
12/09/2020 Christopher Robert Fenimore
VP Controller
1,750   Award at $0 per share. 0
12/09/2020 Christopher Robert Fenimore
VP Controller
969   Award at $0 per share. 0
12/09/2020 Robert E. Landry
EVP Finance CFO
1,930   Award at $0 per share. 0
12/09/2020 Marion McCourt
EVP Commercial
2,000   Award at $0 per share. 0
12/09/2020 Marion McCourt
EVP Commercial
1,075   Award at $0 per share. 0
12/09/2020 Joseph J. LaRosa
EVP General Counsel and Secret
1,930   Award at $0 per share. 0
12/01/2020 Arthur Frederick Ryan
Director
3   Disposition at $524.31 per share. 1,572
12/01/2020 Arthur Frederick Ryan
Director
10   Disposition at $523.32 per share. 5,233
12/01/2020 Arthur Frederick Ryan
Director
14   Disposition at $522.45 per share. 7,314
12/01/2020 Arthur Frederick Ryan
Director
10   Disposition at $521.5 per share. 5,215
12/01/2020 Arthur Frederick Ryan
Director
27   Disposition at $520.58 per share. 14,055
12/01/2020 Arthur Frederick Ryan
Director
13   Disposition at $519.6 per share. 6,754
12/01/2020 Arthur Frederick Ryan
Director
6   Disposition at $518.55 per share. 3,111
12/01/2020 Arthur Frederick Ryan
Director
11   Disposition at $517.63 per share. 5,693
12/01/2020 Arthur Frederick Ryan
Director
4   Disposition at $516.37 per share. 2,065
12/01/2020 Arthur Frederick Ryan
Director
2   Disposition at $515.64 per share. 1,031
11/19/2020 P. Roy Vagelos
Director
2,406   Gift at $0 per share. 0
11/19/2020 P. Roy Vagelos
Director
2,406   Gift at $0 per share. 0
/news/latest/company/us/regn

MarketWatch News on REGN

  1. Regeneron Earnings Lift Stock. Here's Why.

    7:34 a.m. May 6, 2021

    - Josh Nathan-Kazis

  2. Regeneron Q1 REGEN-COV SARS-CoV-2 antibody cocktail sales $262 mln

    6:35 a.m. May 6, 2021

    - Tomi Kilgore

  3. Regeneron Q1 revenue $2.53 bln vs. $1.83 bln a year ago; FactSet consensus $2.50 bln

    6:32 a.m. May 6, 2021

    - Tomi Kilgore

  4. Regeneron Q1 adj. EPS $9.89 vs. $6.60 a year ago; FactSet consensus $8.68

    6:32 a.m. May 6, 2021

    - Tomi Kilgore

  5. Regeneron Q1 EPS $10.09 vs. $5.43 a year ago

    6:32 a.m. May 6, 2021

    - Tomi Kilgore

  6. video content Stock Summer Swoon Coming?

    8:02 a.m. May 3, 2021

    - MarketBrief

  7. Inflation Is Coming. 5 Stocks to Buy Now.

    4:24 p.m. April 27, 2021

    - Jacob Sonenshine

  8. Inflation Is Coming. 5 Stocks to Buy Now.

    4:24 p.m. April 27, 2021

    - Jacob Sonenshine

  9. Buy Moderna Stock. It’s More Than a One-Hit Wonder.

    6:55 a.m. April 26, 2021

    - Josh Nathan-Kazis

  10. Buy Moderna Stock. It’s More Than a One-Hit Wonder.

    1:03 p.m. April 23, 2021

    - Josh Nathan-Kazis

  11. 5 Undervalued Stocks in Biopharma, the Sweet Spot in Healthcare

    5:39 p.m. April 21, 2021

    - Josh Nathan-Kazis

  12. Loading more headlines...
/news/nonmarketwatch/company/us/regn

Other News on REGN

  1. Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts

    5:27 p.m. Today

    - Zacks.com

  2. Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases

    8:07 a.m. Today

    - Zacks.com

  3. Is Sanofi a Good Buy in 2021?

    6:20 a.m. May 12, 2021

    - Motley Fool

  4. Regeneron (REGN) Gets a Buy Rating from BMO Capital

    10:09 a.m. May 7, 2021

    - SmarterAnalyst

  5. Company News for May 7, 2021

    9:29 a.m. May 7, 2021

    - Zacks.com

  6. Wall Street Breakfast: Blowout Payrolls

    7:19 a.m. May 7, 2021

    - Seeking Alpha

  7. Canaccord Genuity Maintains a Buy Rating on Regeneron (REGN)

    6:36 a.m. May 7, 2021

    - SmarterAnalyst

  8. Loading more headlines...

At a Glance

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

Phone

1 9148477000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$8.50B

Net Income

$3.51B

2020 Sales Growth

8.1%

Employees

9,123

/news/pressrelease/company/us/regn

Press Releases on REGN

  1. Uveitis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

    9:06 a.m. May 10, 2021

    - Market Insight Reports

  2. Loading more headlines...
Link to MarketWatch's Slice.